CL2017000867A1 - Composiciones de ácidos grasos y éster de ácido graso autoformadores de micelas y su uso en el tratamiento de patologías - Google Patents

Composiciones de ácidos grasos y éster de ácido graso autoformadores de micelas y su uso en el tratamiento de patologías

Info

Publication number
CL2017000867A1
CL2017000867A1 CL2017000867A CL2017000867A CL2017000867A1 CL 2017000867 A1 CL2017000867 A1 CL 2017000867A1 CL 2017000867 A CL2017000867 A CL 2017000867A CL 2017000867 A CL2017000867 A CL 2017000867A CL 2017000867 A1 CL2017000867 A1 CL 2017000867A1
Authority
CL
Chile
Prior art keywords
compositions
disease
ester
fatty acid
omega
Prior art date
Application number
CL2017000867A
Other languages
English (en)
Inventor
Frederick D Sancilio
Thorsteinn Thorsteinsson
Archibald Glynis Daniel
Toledano Miguel Lopez
Ahmed Abd Almalik Ahmed Mohammed Daak
Original Assignee
Sancilio & Company Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54347886&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017000867(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sancilio & Company Inc filed Critical Sancilio & Company Inc
Publication of CL2017000867A1 publication Critical patent/CL2017000867A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

<p>EN EL PRESENTE DOCUMENTO SE DESCRIBEN COMPOSICIONES QUE INCLUYEN AL MENOS UN ÁCIDO GRASO OMEGA-3 (YA SEA EN FORMA DE TRIGLICÉRIDO, ÉSTER O ÉSTER DE ÁCIDO GRASO LIBRE) Y AL MENOS UN AGENTE TENSIOACTIVO; EN LAS QUE LAS COMPOSICIONES FORMAN MICELAS CUANDO ESTÁN EN CONTACTO CON UN MEDIO ACUOSO. TAMBIÉN SE PROPORCIONAN MÉTODOS DE ADMINISTRACIÓN A UN SUJETO DE UNA COMPOSICIÓN QUE INCLUYE AL MENOS UN ÁCIDO GRASO OMEGA-3 (YA SEA EN FORMA DE TRIGLICÉRIDO, ÉSTER O ÉSTER DE ÁCIDO GRASO LIBRE) Y AL MENOS UN AGENTE TENSIOACTIVO, EN LOS QUE LAS COMPOSICIONES FORMAN MICELAS CUANDO ESTÉN EN CONTACTO CON UN MEDIO ACUOSO Y LA BIODISPONIBILIDAD DEL ÁCIDO GRASO OMEGA-3 ES SUSTANCIALMENTE INDEPENDIENTE DE UN EFECTO DE LOS ALIMENTOS. LAS COMPOSICIONES SON ÚTILES PARA EL TRATAMIENTO DE CIERTAS PATOLOGÍAS QUE PUEDEN INCLUIR (1) SÍNDROMES DE MALABSORCIÓN, (2) COLANGITIS ESCLEROSANTE PRIMARIA (CEP), (3) HÍGADO GRASO NO ALCOHÓLICO (HGNA), 4) ENFERMEDAD DREPANOCÍTICA (ED), (5) DEGENERACIÓN MACULAR ASOCIADA A LA EDAD (DMAE). (6) ENFERMEDAD NEURODEGENERATIVA, INCLUYENDO LA ENFERMEDAD DE PARKINSON (EP), LA ENFERMEDAD DE ALZHEIMER (EA), LA ESCLEROSIS LATERAL AMIOTRÓFICA (ELA O ENFERMEDAD DE LOU GEHRIG). LA EPILEPSIA, EL SÍNDROME BIPOLAR, EL TRAUMATISMO CRANEOENCEFÁLICO, LA NEUROPATÍA PERIFÉRICA Y LA ESCLEROSIS MÚLTIPLE (EM). TAMBIÉN SE DESCRIBEN DIVERSAS FORMAS DE DOSIFICACIÓN PARA LA ADMINISTRACIÓN DE LAS COMPOSICIONES Y EL USO DE LAS COMPOSICIONES EN ALIMENTOS FUNCIONALES. EN EL PRESENTE DOCUMENTO TAMBIÉN SE PROPORCIONAN KITS CN INSTRUCCIONES PARA SU ADMINISTRACIÓN.</p>
CL2017000867A 2014-10-10 2017-04-10 Composiciones de ácidos grasos y éster de ácido graso autoformadores de micelas y su uso en el tratamiento de patologías CL2017000867A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462062634P 2014-10-10 2014-10-10
US201462062646P 2014-10-10 2014-10-10
US201462062638P 2014-10-10 2014-10-10
US201462062652P 2014-10-10 2014-10-10
US201462062651P 2014-10-10 2014-10-10
US201462062643P 2014-10-10 2014-10-10

Publications (1)

Publication Number Publication Date
CL2017000867A1 true CL2017000867A1 (es) 2017-11-03

Family

ID=54347886

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000867A CL2017000867A1 (es) 2014-10-10 2017-04-10 Composiciones de ácidos grasos y éster de ácido graso autoformadores de micelas y su uso en el tratamiento de patologías

Country Status (8)

Country Link
EP (1) EP3212236A1 (es)
BR (1) BR112017007428A2 (es)
CA (1) CA2963952C (es)
CL (1) CL2017000867A1 (es)
MA (1) MA40846A (es)
MX (2) MX2017004324A (es)
WO (1) WO2016057915A1 (es)
ZA (1) ZA201702385B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106692973A (zh) * 2015-11-13 2017-05-24 深圳君圣泰生物技术有限公司 一种组合物及其用途、药物制剂
AU2016406709C1 (en) * 2016-05-10 2023-04-27 Shenzhen Hightide Biopharmaceutical., Ltd. Composition, and application and pharmaceutical preparation thereof
US11241408B2 (en) 2016-08-12 2022-02-08 Pharmako Biotechnologies Pty Limited Omega-3 compositions and methods relating thereto
CN110312509A (zh) * 2017-02-07 2019-10-08 费森尤斯卡比德国有限公司 使用epa和dha的肝病治疗的长期功效
FR3092968B1 (fr) * 2019-02-22 2021-05-21 Microphyt Complement alimentaire
IT201900007202A1 (it) * 2019-05-24 2020-11-24 Pavia Farm S R L Composizione a base di vitamine liposolubili ad elevato assorbimento enterico
MX2022001238A (es) 2019-08-13 2022-07-13 Team Foods Colombia Sa Composicion lipidica que comprende antioxidantes y polifenoles naturales como alternativa no farmacologica para el tratamiento y la prevencion de nafld.
CN115737555B (zh) * 2022-05-20 2024-06-21 深圳海王医药科技研究院有限公司 一种千金藤素自微乳组合物、制剂及其制备方法
CN117730823A (zh) * 2022-09-20 2024-03-22 上海中医药大学 原发性硬化性胆管炎合并炎症性肠病的造模方法
WO2026030644A1 (en) * 2024-07-31 2026-02-05 Caper Labs, Inc. Arachidonic acid therapy for the treatment of neutropenia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2433630A4 (en) * 2009-05-22 2014-01-08 Mochida Pharm Co Ltd SELF-EMULSIFIABLE COMPOSITION OF FATTY ACID 3
WO2012032414A2 (en) * 2010-09-08 2012-03-15 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture, a surfactant, and a statin
EP2793867B1 (en) * 2011-12-22 2021-01-20 Baes, Erik Gelatin/alginate delayed release capsules comprising omega-3 fatty acids, and methods and uses thereof
EP3072510B1 (en) * 2012-03-30 2019-05-08 Micelle BioPharma, Inc. Omega-3 fatty acid ester compositions

Also Published As

Publication number Publication date
CA2963952A1 (en) 2016-04-14
WO2016057915A1 (en) 2016-04-14
MX2020002238A (es) 2020-07-13
ZA201702385B (en) 2020-12-23
EP3212236A1 (en) 2017-09-06
MA40846A (fr) 2017-09-05
MX2017004324A (es) 2017-07-04
CA2963952C (en) 2023-10-17
BR112017007428A2 (pt) 2017-12-19

Similar Documents

Publication Publication Date Title
CL2017000867A1 (es) Composiciones de ácidos grasos y éster de ácido graso autoformadores de micelas y su uso en el tratamiento de patologías
CO7121328A2 (es) Composiciones de ester de ácido graso omega -3
CL2019001447A1 (es) Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos.
CY1123942T1 (el) Συνθεσεις ωμεγα-3 λιπαρων οξεων για τη θεραπεια ασθενειων που επιφερουν βλαβη στο νευρικο συστημα
PH12018500090A1 (en) Nutritional compositions and methods for promoting cognitive development
HK1206248A1 (en) Compositions of statins and omega-3 fatty acids
HK1202415A1 (en) Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of use thereof
PH12017500467A1 (en) Nutritional compositions comprising sn-1(3) monoacylglycerols for use in the treatment of malabsorption or maldigestion in infants or children
AR105237A1 (es) Método y composiciones nutricionales que contienen fosfatidiletanolamina, esfingomielina y ácido docosahexaenoico
PH12018500035A1 (en) Nutritional compositions and methods for promoting cognitive development
MX2022011742A (es) Composicion nutritiva para el entorno gastrointestinal para proporcionar microbioma y perfil metabolico mejorados.
PH12014500859A1 (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
CL2018003537A1 (es) Lípidos con un número impar de átomos de carbono y su uso como una composición farmacéutica o como un suplemento nutricional.
MX2021002902A (es) Composicion farmaceutica para prevenir o tratar la enfermedad del higado graso no alcoholico, que contiene ligando gpr119 como principio activo.
CL2019000766A1 (es) Composiciones de éster de colina de ácido lipoico y métodos para estabilizar en productos farmacológicos farmacéuticamente relevantes.
HK1244218A1 (zh) 包括多不饱和游离脂肪酸的毫米胶囊配制品
AR100028A1 (es) Composiciones nutricionales que contienen ácido estearidónico
ES2527366B1 (es) Composición detergente que comprende un biosurfactante de origen vegetal
CL2015001104A1 (es) Composición de la alimentación para peces
BR112018071142A2 (pt) métodos de fabricação de formulações nutricionais
BR112018070194A2 (pt) composto e composição para uso
ECSP15011105A (es) siRNA Y SU USO EN LOS MÉTODOS Y COMPOSICIONES PARA EL TRATAMIENTO Y/O PREVENCIÓN DE TRASTORNOS OCULARES
AR097148A1 (es) Composición alimenticia para rumiantes y método para prepararla
WO2015123480A3 (en) Compositions and methods for the prevention and/or treatment of schistosomiasis
TH128490A (th) องค์ประกอบสำหรับทำความสะอาดผิวที่มีโพลิกลีเซอรอลเอสเตอร์และโพลิเมอร์ที่ดัดแปรให้มีสภาพไม่ชอบน้ำ